Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syros Pharmaceuticals (NQ: SYRS )

0.1988 -0.0605 (-23.33%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Syros Pharmaceuticals

< Previous 1 2 3 4 Next >
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
From Syros Pharmaceuticals
Via Business Wire
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
From Syros Pharmaceuticals
Via Business Wire
SYRS Investors Have Opportunity to Join Syros Pharmaceuticals, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update
From Syros Pharmaceuticals
Via Business Wire
Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
From Syros Pharmaceuticals
Via Business Wire
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
From Syros Pharmaceuticals
Via Business Wire
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Syros to Participate in Upcoming Investor Conferences
From Syros Pharmaceuticals
Via Business Wire
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
From Syros Pharmaceuticals
Via Business Wire
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
From Syros Pharmaceuticals
Via Business Wire
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
From Syros Pharmaceuticals
Via Business Wire
Syros to Participate in TD Cowen 44th Annual Health Care Conference
From Syros Pharmaceuticals
Via Business Wire
Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
From Syros Pharmaceuticals
Via Business Wire
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Syros Pharmaceuticals
Via Business Wire
Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
From Syros Pharmaceuticals
Via Business Wire
Syros to Participate in Upcoming Investor Conferences
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
From Syros Pharmaceuticals
Via Business Wire
Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.